Pfizer is seeking FDA approval for its oral Covid-19 antiviral Paxlovid, an anticipated move that could boost confidence in the drug and set the stage for the company to market directly to consumers.
Paxlovid is being sought for FDA approval.
Pfizer is trying to get the FDA to approve Paxlovid for use in people at risk of Covid-19.
Paxlovid is only available under an emergency use authorization, which restricts who Pfizer can sell the drug to, restricts advertising and communications on the drug, and only allows it to remain on the market during an emergency.
Roughly 50% to 60% of the population who have at least one risk factor for severe illness that would make them eligible for Paxlovid are covered by Pfizer's application.
Paxlovid reduced the risk of hospitalization or death when taken within five days of symptoms.
Paxlovid is an important treatment option for patients at risk of severe disease regardless of their vaccine status, according to Pfizer chairman and chief executive Albert Bourla.
Paxlovid has been approved for use in Covid 19. It was hailed as a game-changing development in the fight against the Pandemic, plugging a crucial gap between caring for those seriously unwell in hospital and preventing illness in the first place through vaccine. Even though initial supply issues had been overcome, the White House wanted the drug to be used more. Reports of rebound infections when taking Paxlovid are being investigated by experts and officials. The Centers for Disease Control, along with experts like Dr. Anthony Fauci, stressed that this could be a natural part of the Covid infections in some people, regardless of treatment or vaccine status.
More than 1.5 million. Data from the Department of Health and Human Services shows how many Paxlovid courses have been administered in the U.S.
After taking Paxlovid, can Covid symptoms return to normal? The New York Times.
Live updates on the coronaviruses.
All Rights Reserved © 2024
